Literature DB >> 14530904

Modulation of Fas receptor proteins and dynamin during opiate addiction and induction of opiate withdrawal in rat brain.

M Julia García-Fuster1, Marcel Ferrer-Alcón, Antonio Miralles, Jesús A García-Sevilla.   

Abstract

The Fas receptor is involved in the regulation of apoptosis but also can function as a non-apoptotic signal transducer. This study was mainly designed to quantitate Fas proteins in rat brain during heroin addiction and opiate withdrawal. In rat, mouse and human brains, and in SH-SY5Y cells, similar forms of Fas were immunodetected with different antibodies (i.e., 35 kDa native Fas and 48- and 51-kDa glycosylated Fas). Acute (2 h) treatments with the micro-opioid receptor agonists heroin (10 mg/kg) and morphine (30 mg/kg) increased the immunodensity of native Fas (124% and 36%) but not that of glycosylated Fas in the cerebral cortex. Chronic (5 days) heroin (5-30 mg/kg) and morphine (10-100 mg/kg) were also associated with increased native Fas (76% and 45%) and with different expressions of glycosylated Fas. In heroin-dependent rats, opiate withdrawal (48 h) resulted in a sustained increase in native Fas (107%) and in up-regulation of 51 kDa glycosylated Fas (51%). Acute treatments with selective delta-receptor (SNC-80, 10 mg/kg) or kappa-receptor (U 50488-H, 10 mg/kg) agonists did not alter the content of native or glycosylated Fas. Chronic pentazocine (10-80 mg/kg, 5 days), a mixed opiate drug and sigma(1) receptor agonist, decreased native (48%) and glycosylated (38-82%) Fas proteins. Similarly, the selective sigma(1) agonist (+)-SKF 10047 also decreased native Fas (37%) and the effect was blocked by the sigma(1) antagonist BD 1063. Brain dynamin was up-regulated by acute and/or chronic heroin (30-39%), morphine (47-85%), pentazocine (51%) and heroin withdrawal (74%). The main results indicate that chronic heroin/morphine treatment and heroin withdrawal are associated with up-regulation of 35 kDa native Fas (and with different expressions of glycosylated Fas), and also with concomitant increases of dynamin in rat brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530904     DOI: 10.1007/s00210-003-0801-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  49 in total

1.  Overexpression of dynamin is induced by chronic stimulation of mu- but not delta-opioid receptors: relationships with mu-related morphine dependence.

Authors:  F Noble; M Szücs; B Kieffer; B P Roques
Journal:  Mol Pharmacol       Date:  2000-07       Impact factor: 4.436

Review 2.  Structure and function of Fas/Fas ligand.

Authors:  J R Orlinick; A K Vaishnaw; K B Elkon
Journal:  Int Rev Immunol       Date:  1999       Impact factor: 5.311

3.  Staurosporine- and H-7-induced cell death in SH-SY5Y neuroblastoma cells is associated with caspase-2 and caspase-3 activation, but not with activation of the FAS/FAS-L-caspase-8 signaling pathway.

Authors:  E López; I Ferrer
Journal:  Brain Res Mol Brain Res       Date:  2000-12-28

4.  FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier.

Authors:  I Bechmann; G Mor; J Nilsen; M Eliza; R Nitsch; F Naftolin
Journal:  Glia       Date:  1999-07       Impact factor: 7.452

5.  The Fas/FasL apoptotic pathway is involved in kappa-opioid-induced apoptosis of human endometrial stromal cells.

Authors:  E Chatzaki; A Makrigiannakis; A N Margioris; E Kouimtzoglou; A Gravanis
Journal:  Mol Hum Reprod       Date:  2001-09       Impact factor: 4.025

6.  Chronic morphine induces up-regulation of the pro-apoptotic Fas receptor and down-regulation of the anti-apoptotic Bcl-2 oncoprotein in rat brain.

Authors:  M A Boronat; M J García-Fuster; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

7.  Mu-opioid receptor mediates chronic restraint stress-induced lymphocyte apoptosis.

Authors:  Jinghua Wang; Richard Charboneau; Roderick A Barke; Horace H Loh; Sabita Roy
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

8.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.

Authors:  A Oehm; I Behrmann; W Falk; M Pawlita; G Maier; C Klas; M Li-Weber; S Richards; J Dhein; B C Trauth
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

9.  Spontaneous withdrawal from long-term treatment with morphine accelerates the turnover of alpha 2-adrenoceptors in the rat brain: up-regulation of receptors associated with increased receptor appearance.

Authors:  A M Gabilondo; J A García-Sevilla
Journal:  J Neurochem       Date:  1995-06       Impact factor: 5.372

10.  Chronic restraint stress promotes lymphocyte apoptosis by modulating CD95 expression.

Authors:  D Yin; D Tuthill; R A Mufson; Y Shi
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

View more
  12 in total

1.  Decreased proliferation of adult hippocampal stem cells during cocaine withdrawal: possible role of the cell fate regulator FADD.

Authors:  M Julia García-Fuster; Shelly B Flagel; S Taha Mahmood; Leah M Mayo; Robert C Thompson; Stanley J Watson; Huda Akil
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

Review 2.  Genes and pathways co-associated with the exposure to multiple drugs of abuse, including alcohol, amphetamine/methamphetamine, cocaine, marijuana, morphine, and/or nicotine: a review of proteomics analyses.

Authors:  Ju Wang; Wenji Yuan; Ming D Li
Journal:  Mol Neurobiol       Date:  2011-09-16       Impact factor: 5.590

3.  Distinctive profiles of gene expression in the human nucleus accumbens associated with cocaine and heroin abuse.

Authors:  Dawn N Albertson; Carl J Schmidt; Gregory Kapatos; Michael J Bannon
Journal:  Neuropsychopharmacology       Date:  2006-05-03       Impact factor: 7.853

4.  Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain.

Authors:  Glòria Salort; María Álvaro-Bartolomé; Jesús A García-Sevilla
Journal:  Psychopharmacology (Berl)       Date:  2017-01-26       Impact factor: 4.530

5.  Persistent proteomic alterations in the medial prefrontal cortex with abstinence from cocaine self-administration.

Authors:  Melinda E Lull; Mandi S Erwin; Drake Morgan; David C S Roberts; Kent E Vrana; Willard M Freeman
Journal:  Proteomics Clin Appl       Date:  2009-03-17       Impact factor: 3.494

6.  Effect of cocaine on Fas-associated protein with death domain in the rat brain: individual differences in a model of differential vulnerability to drug abuse.

Authors:  María-Julia García-Fuster; Sarah M Clinton; Stanley J Watson; Huda Akil
Journal:  Neuropsychopharmacology       Date:  2008-06-25       Impact factor: 7.853

7.  Cerebellar neuronal apoptosis in heroin-addicted rats and its molecular mechanism.

Authors:  Hongwei Pu; Xuemei Wang; Jianlong Zhang; Chuang Ma; Yinxia Su; Xiujuan Li; Xiaoshan Liu; Liping Su
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

8.  Chronic Opium Treatment Can Differentially Induce Brain and Liver Cells Apoptosis in Diabetic and Non-diabetic Male and Female Rats.

Authors:  Majid Asiabanha; Gholamreza Asadikaram; Amir Rahnema; Mehdi Mahmoodi; Gholamhosein Hasanshahi; Mohammad Hashemi; Mohammad Khaksari
Journal:  Korean J Physiol Pharmacol       Date:  2011-12-27       Impact factor: 2.016

9.  Chronic methadone treatment and repeated withdrawal impair cognition and increase the expression of apoptosis-related proteins in mouse brain.

Authors:  Mónica Tramullas; Carmen Martínez-Cué; María A Hurlé
Journal:  Psychopharmacology (Berl)       Date:  2007-03-24       Impact factor: 4.415

10.  Ovary cells apoptosis in opium-addicted diabetic and non-diabetic rats.

Authors:  Gholamreza Asadikaram; Majid Asiabanha; Majid Sirati Sabet
Journal:  Int J High Risk Behav Addict       Date:  2013-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.